3,9-Diethyl-3,9-dimethyl-2,4,8,10-tetraoxaspiro<5,5>undecan | 5703-82-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,9-Diethyl-3,9-dimethyl-2,4,8,10-tetraoxaspiro<5,5>undecan
• 英文别名: Pentaerythrit-bis-；3,9-diethyl-3,9-dimethyl-2,4,8,10-tetraoxa-spiro[5.5]undecane；3,9-Diethyl-3,9-dimethyl-2,4,8,10-tetraoxaspiro[5.5]undecane
• CAS: 5703-82-2
• 化学式: C₁₃H₂₄O₄
• 分子量: 244.331
• InChiKey: RXHIZBRUSCIQBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  3,9-Diethyl-3,9-dimethyl-2,4,8,10-tetraoxaspiro<5,5>undecan 在 溴 作用下， 以 乙醚 为溶剂， 反应 1.0h， 以78%的产率得到3,9-Bis(1-bromoethyl)-3,9-bis(bromomethyl)-2,4,8,10-tetraoxaspiro<5.5>undecane
  参考文献：
  名称：

  Zur Stereochemie einiger neuer chiraler Bromverbindungen mit einem 2,4,8,10-Tetraoxaspiro[5.5]-undecan ? Ger�st

  摘要：

  New compounds containing the 2,4,8,10-tetraoxaspiro[5.5] undecanic skeleton, substituted with brominated groups, have been synthesized by a regioselective radicalic bromination reaction. The stereochemistry of the compounds was studied by high resolution NMR methods. The anancomericity or the flipping of the rings was inferred from the conformational analysis. The chirality of the spiranic skeleton was investigated by means of the diastereotopicity of hydrogen and carbon atoms.

  DOI：

  10.1007/bf00811022
• 作为产物：
  描述：

  季戊四醇 、 丁酮 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 3,9-Diethyl-3,9-dimethyl-2,4,8,10-tetraoxaspiro<5,5>undecan
  参考文献：
  名称：

  Stereochemie und1H-NMR-Spektren einiger vom Pentaerythrit abgeleiteten Spiro-1,3-dioxane

  摘要：

  DOI：

  10.1007/bf00809966

文献信息

• A Facile, Selective Preparation of Monoketals from Pentaerythritol and Ketones
  作者：Ricardo Grau、Marcelo Murguía、Santiago Vaillard

  DOI：10.1055/s-2001-14569

  日期：——

  The selective preparation of monoketals 3a-f from pentaerythritol 1 and cyclic, acyclic, aromatic, and aliphatic ketones 2a-f was achieved by a facile method. The extreme polarity and low solubility of pentaerythritol in almost all organic solvents were the main difficulties to be overcome for the preparation of monoketals in good yields and high selectivity. A benzene-dimethylformamide (40:60) mixture proved to be excellent for the ketalization. The one-step procedure developed allowed the preparation of monoketals in good yields and good to excellent selectivity (higher than 90%).

  通过一种简便的方法成功地从五羟基醇1和环状、非环状、芳香族和脂肪族酮2a-f选择性制备了单酮基化合物3a-f。五羟基醇在几乎所有有机溶剂中的极高极性和低溶解度是制备单酮基化合物时主要需要克服的困难。实验表明，苯-二甲基甲酰胺（40:60）混合物在酮基化反应中表现优异。所开发的一步法程序使得单酮基化合物的制备在良好收率和良好至优异选择性（超过90%）下得以实现。
• Spirocyclic acetal compound and method of producing the same, and polymer having spirocyclic acetal structure
  申请人：Ito Takayuki

  公开号：US20070191584A1

  公开（公告）日：2007-08-16

  A method of producing a spirocyclic acetal compound of formula (II), having subjecting a compound of formula (I) and pentaerythritol to dehydration condensation, in the presence of a solid acid catalyst; and the polymer having a repeating unit represented by formula (III), which is produced using the spirocyclic acetal compound of formula (II): wherein R 1 represents an alkyl, cycloalkyl or aryl group, Q represents a hydrogen atom or an acyl group, L represents a divalent linking group having at least one carbon atom, and n is 0 or 1

  一种制备公式（II）的螺环缩醛化合物的方法，包括在固体酸催化剂存在下，将公式（I）的化合物和五羟基甲基糖醇进行脱水缩合；以及使用公式（II）的螺环缩醛化合物制备具有重复单元公式（III）的聚合物：其中，R1代表烷基、环烷基或芳基基团，Q代表氢原子或酰基基团，L代表至少有一个碳原子的二价连接基团，n为0或1。
• US7605276B2
  申请人：——

  公开号：US7605276B2

  公开（公告）日：2009-10-20
• US8007938B2
  申请人：——

  公开号：US8007938B2

  公开（公告）日：2011-08-30
• [EN] PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT DES COMPOSÉS ANTIÉMÉTIQUES ET UN POLYORTHOESTHER
  申请人：A P PHARMA INC

  公开号：WO2014093907A1

  公开（公告）日：2014-06-19

  The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1 ) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration. Also described are methods of treatment of various disorders, including chemotherapy-induced nausea and vomiting (CINV). The disclosed compositions and methods provide for less frequent dosing of the therapeutic agents, thereby increasing subject comfort and compliance.